Cargando…
LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ
AIMS: To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and morbidity. METHODS: Baseline data, stratified for prior cardiovascular...
Autores principales: | Rutten, Guy E. H. M., Tack, Cees J., Pieber, Thomas R., Comlekci, Abdurrahman, Ørsted, David Dynnes, Baeres, Florian M. M., Marso, Steven P., Buse, John B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891842/ https://www.ncbi.nlm.nih.gov/pubmed/27274772 http://dx.doi.org/10.1186/s13098-016-0153-5 |
Ejemplares similares
-
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
por: Masmiquel, L., et al.
Publicado: (2016) -
LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
por: Steinberg, William M., et al.
Publicado: (2014) -
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
por: Petrie, John R., et al.
Publicado: (2016) -
Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018) -
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)